Rigel Pharmaceuticals (RIGL) caught the market’s eye after reporting record sales for the third quarter, strong annual growth in revenue and net income, and raising its 2025 revenue forecast above ...
The TRAVOCA Rigel DZ combines premium materials, precision engineering, and all-terrain durability into an electric cooler that chills and freezes wherever you roam.
Rigel's Q2 results were outstanding, with revenue nearly doubling and net income surging, driven by strong commercial momentum for TAVALISSE, GAVRETO, and REZLIDHIA. Management raised 2025 guidance, ...
Hosted on MSN
Rigel (RIGL) Loses 27.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Rigel Pharmaceuticals (RIGL) has been beaten down lately with too much selling pressure. While the stock has lost 27% over the past four weeks, there is light at the end of the tunnel as it is now in ...
Rigel Pharmaceuticals is a commercial-stage biotech growing revenue with three marketed drugs and a promising pipeline. RIGL's product sales grew 72% YoY in 1H FY2025, with diversification reducing ...
Rigel will participate in one-on-one meetings and present a company overview on Wednesday, September 3, at 8:35 a.m. ET. 2025 Wells Fargo Healthcare Conference in Boston, MA Rigel will participate in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback